The U.S. FDA announced today its decision to approve AGAMREE (vamorolone), a new steroid for individuals with Duchenne muscular dystrophy 2 years or older. This approval comes largely based on […]
Thank You to Our Sponsors! .
SEE UPDATE FROM OCTOBER 30, 2023 HERE CLICK BELOW FOR A FEW WORDS FROM OUR TEAM AND SAREPTA: Sarepta Therapeutics’ gene therapy for Duchenne, SRP-9001, has been granted Accelerated Approval […]
NEW YORK, June 15, 2023 – CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative clinical trial grant to test repurposing of the FDA-approved […]
Como parte de nuestra misión de avanzar en la investigación hacia tratamientos transformadores para todas las personas con Duchenne, CureDuchenne ha hecho que nuestro biobanco integrado de datos, CureDuchenne Link, […]
Newport Beach, Calif. (May 11, 2023) – CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD). […]
The last day of FUTURES 2023 was jam-packed with sessions focused on how people with Duchenne can use their lived experience to help others going through the same challenges. A Game of Life encouraged people to share tips and tricks that work for them, breakout sessions met people wherever they were at in their Duchenne journey, and the closing session was an opportunity for everyone to share what was on their mind.
Edgewise Therapeutics, which received early funding from CureDuchenne, announced positive 6-month interim results from the ongoing ARCH study, an open label study of EDG-5506 in adults with Becker muscular dystrophy. Edgewise […]
Palm Springs-themed Event Supports Global Nonprofit Focused on Finding and Funding a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 23, 2022) – CureDuchenne, a leading global nonprofit focused […]
